Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes.

Abstract

INTRODUCTION

We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD).

METHODS

Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020.

RESULTS

574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean lipid-density lipoprotein cholesterol was 85 mg/dl, mean glycated hemoglobin HbA(1c) 7.1%, mean triglycerides 148 mg/dl; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA.

CONCLUSIONS

In this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.